Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Trial to Assess the Safety and Efficacy of Burosumab (KRN23), an Investigational Antibody to FGF23, in a Single Pediatric Patient With Epidermal Nevus Syndrome(ENS) and Associated Hypophosphatemic Rickets

NCT03581591 is registered in ClinicalTrials.gov with Redwood Dermatology Sciences as lead sponsor.

NCT NCT03581591
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03581591 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Trial to Assess the Safety and Efficacy of Burosumab (KRN23), an Investigational Antibody to FGF23, in a Single Pediatric Patient With Epidermal Nevus Syndrome(ENS) and Associated Hypophosphatemic Rickets
Lead sponsor
Redwood Dermatology Sciences
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2018
Completion date
December 6, 2019
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypophosphatemia, hypophosphatemic rickets, pain, chronic